Form 4: Baker Bros. Advisors Increase Stake in IGM Biosciences (IGMS) Through Multiple Transactions

Baker Bros. Advisors LP and affiliated entities report acquiring additional shares of IGM Biosciences (IGMS) common stock across several transactions in late March 2024, increasing their beneficial ownership.

Summary

• Baker Bros. Advisors LP, along with related entities including 667, L.P. and Baker Brothers Life Sciences, L.P., have reported changes in their beneficial ownership of IGM Biosciences (IGMS) common stock.
• Between March 26 and March 28, 2024, the entities acquired shares through multiple transactions at prices ranging from $8.22 to $9.65 per share.
• The purchases resulted in an increase in the number of shares beneficially owned indirectly by these entities.
• Felix J. Baker and Julian C. Baker, through their affiliations with Baker Bros. Advisors LP and related entities, may be deemed to have an indirect pecuniary interest in the shares.
• The reporting persons have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock purchases. While increased investment can be seen as positive, it's not overwhelmingly so without further context.

Positives

• Increased investment by Baker Bros. Advisors could signal confidence in IGM Biosciences' future prospects.

Industry Context

Form 4 filings are standard disclosures for significant shareholders, providing transparency into their investment activities. Baker Bros. Advisors is a well-known healthcare investment firm, so their activity in IGMS is noteworthy for the biotech industry.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for insiders and large shareholders, ensuring transparency in the market.
• The reported transactions are similar to those of other investment firms that actively manage their positions in publicly traded companies.
• The level of detail provided in the footnotes regarding weighted average prices and indirect ownership is consistent with industry best practices for Form 4 filings.

Stakeholder Impact

• The increased stake by Baker Bros. Advisors could be viewed positively by shareholders, potentially influencing investor confidence.
• The transactions themselves have a limited direct impact on employees, customers, suppliers, or creditors.

Key Dates